BiomX Inc. (NYSEAMERICAN:PHGE – Free Report) – Investment analysts at HC Wainwright upped their FY2025 EPS estimates for BiomX in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($1.90) per share for the year, up from their previous forecast of ($2.92). HC Wainwright currently has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for BiomX’s current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for BiomX’s FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at ($1.84) EPS.
BiomX Stock Performance
NYSEAMERICAN:PHGE opened at $0.63 on Thursday. The stock has a market capitalization of $11.44 million, a price-to-earnings ratio of -0.20 and a beta of 1.27. BiomX has a 12-month low of $0.48 and a 12-month high of $4.99.
BiomX Company Profile
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
Featured Articles
- Five stocks we like better than BiomX
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Tesla Stock: What To Expect With Their Delivery Numbers Report
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock
- Retail Stocks Investing, Explained
- Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
